Clinical Trials Logo
  1. Home
  2. EBV-Positive DLBCL, Nos
  3. NCT04705129

Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL

Primary Mediastinal Large B Cell Lymphoma Clinical Trial

Official title:
A Phase II Study on the Safety and Efficacy of Zanubrutinib Combined With Tislelizumab in the Treatment of Relapsed/Refractory Primary Mediastinal Large B-cell Lymphoma and Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma

Clinical Trial Summary

The study is to investigate the safety and efficacy of Zanubrutinib combined with Tislelizumab in the treatment of relapsed/refractory primary mediastinal large B-cell lymphoma and Epstein-Barr Virus-positive diffuse large B-cell lymphoma.

Clinical Trial Description

R-CHOP regimen is the first-line therapy in DLBCL which greatly improved the efficacy of diffuse large B-cell lymphoma (DLBCL) and achieved good long-term survival. However, among DLBCL patients treated with R-CHOP, EBV+ had a lower 5-year OS than EBV- patients (65% vs 82%). For primary mediastinal large B-cell lymphoma (PMBCL), although the initial treatment has a better prognosis than DLBCL, there are still 10% to 30% of PMBCL patients with primary refractory or relapsed disease, and the prognosis is poor. Zanubrutinib combined with Tislelizumab has been proved efficient in relapsed or refractory NHLs, with ORR rate 37%, CR rate of 16.7%. This phase II, prospective, open-label, single-arm study will evaluate the efficacy and safety of Zanubrutinib combined with Tislelizumab in the treatment of relapsed/refractory primary mediastinal large B-cell lymphoma and Epstein-Barr Virus-positive diffuse large B-cell lymphoma. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04705129
Study type Interventional
Source Ruijin Hospital
Contact Weili Zhao, PhD, MD
Phone +862164370045
Email zwl_trial@163.com
Status Recruiting
Phase Phase 2
Start date January 1, 2021
Completion date January 1, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04545762 - Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Phase 1
Recruiting NCT05934448 - Pembro Plus CAR T-cell Therapy in R/R in PMBCL Phase 2
Recruiting NCT05326243 - Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma Phase 1/Phase 2
Completed NCT04323657 - TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia Phase 1/Phase 2
Terminated NCT04844086 - RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies Phase 1
Active, not recruiting NCT04067414 - Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma Phase 1
Active, not recruiting NCT04464200 - 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers Phase 1
Recruiting NCT05653271 - ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies Phase 1
Enrolling by invitation NCT04488354 - Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T Phase 1
Recruiting NCT05377307 - Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
Withdrawn NCT04503538 - Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity N/A
Active, not recruiting NCT04542824 - Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL Phase 1/Phase 2
Active, not recruiting NCT04450069 - CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies Phase 1
Recruiting NCT05544019 - Study of SGR-1505 in Mature B-Cell Neoplasms Phase 1
Active, not recruiting NCT01516567 - Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation Phase 2